Higher medical equipment procurement costs due to global inflation and yen depreciation
First written in FY2023-Q1. 6 of 8 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2019: 10 of 16 companies on the "Worse" side.
10 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「In addition, although purchasing prices for medical equipment continue to rise amid the global surge in prices, we negotiate to pass the increases through to selling prices wherever possible while also proposing lower-priced alternatives that meet customer needs.」
The company continues to disclose the risk of ongoing increases in purchase prices amid global inflation, and identifies proposals for lower-cost alternatives and negotiations to pass the increases through to selling prices as response measures. - FY2025-H1RestatedAnnual report
「Although purchase prices for medical devices continue to rise amid global inflation, we are negotiating to pass the increases through to selling prices as far as possible, while also proposing lower-cost alternatives that meet customer needs.」
Purchase prices for medical devices have continued to rise due to global inflation. The company continues to propose lower-cost alternatives and negotiate to pass the increases through to selling prices as response measures. - FY2024RestatedAnnual report
「Although purchasing prices for medical equipment continue to rise amid the global surge in prices, the company continues to negotiate persistently to pass the increases through to selling prices.」
Purchase prices for medical devices have continued to rise due to global inflation, and negotiations to pass the increases through to selling prices are being continued as a response measure. - FY2024-Q2RestatedAnnual report
「Meanwhile, purchase prices for medical equipment have continued to rise amid global price inflation, but we have continued to negotiate persistently to pass the increases on to selling prices.」
Purchase prices for medical devices have continued to rise amid global inflation, and negotiations to pass the increases through to selling prices are ongoing. - FY2024-Q1RestatedAnnual report
「Meanwhile, purchase prices for medical equipment have continued to rise amid global price inflation, but we have continued to negotiate persistently to pass the increases on to selling prices.」
Purchase prices for medical devices have continued to rise amid global inflation. The company also describes its response of persistently negotiating to pass the increases through to selling prices. - FY2023MitigatedAnnual report
「Although purchase prices rose due to global inflation, we were able to secure a certain level of profit as we made progress in passing the increases on to selling prices.」
The company states that purchase prices for imported medical devices have continued to rise due to global inflation, but that the pass-through to selling prices has progressed and a certain level of profitability has been secured. - FY2023-Q2RestatedAnnual report
「Meanwhile, purchase price increases for medical equipment, much of which is imported, have continued due to global inflation and the weaker yen.」
The company states that higher purchase prices for imported medical devices due to global inflation and the weaker yen have continued. - FY2023-Q1First statedAnnual report
「Meanwhile, the purchase prices of medical equipment, much of which is imported, have been trending upward due to global inflation and the weaker yen.」
The company has disclosed a new external-environment risk: purchase prices for medical devices with a high import dependency are trending higher due to global inflation and the weaker yen.